Trial Profile
A Multi-center, Single-arm Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Male and Female Participants ≥2 Years to <12 Years of Age With Uncontrolled Chronic Spontaneous Urticaria (CSU)
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 15 Mar 2024
Price :
$35
*
At a glance
- Drugs Dupilumab (Primary)
- Indications Chronic urticaria
- Focus Pharmacokinetics; Registrational
- Acronyms CINDU CUPIDKids; LIBERTY-CSU; LIBERTY-CSU/CINDU CUPIDKids
- Sponsors Sanofi
- 23 Aug 2023 Planned End Date changed from 7 Jun 2024 to 7 Jul 2025.
- 23 Aug 2023 Planned primary completion date changed from 29 Mar 2024 to 1 Mar 2025.
- 05 Sep 2022 New trial record